Publications by authors named "T C Cunningham"
Background: Epidermolysis bullosa (EB) is a group of rare, severe, genetic disorders characterised by persistent skin fragility and open wounds. EB manifests as cutaneous and mucosal blistering, erosions and impaired wound healing.
Objectives: To determine the long-term efficacy, tolerability and safety of Oleogel-S10 (birch bark extract) in dystrophic (DEB) and junctional (JEB) EB in the 24-months open-label phase (OLP) of the EASE study.
Article Synopsis
- - This study looks at how sleep disturbances affect emotional well-being daily, with a focus on how exercise and social interaction might play a role in this relationship.
- - Using data from 455 participants over 20 days, researchers found that better sleep efficiency leads to more positive feelings and less negative feelings, while poor sleep quality has the opposite effect.
- - The study revealed that exercise can help lessen the negative impact of bad sleep on emotions, while more social interaction can enhance the benefits of good sleep on emotional health.
Article Synopsis
- The National Ignition Facility is exploring the use of Agfa D4 film to enhance spectral resolution for x-ray imaging in high-energy-density experiments.
- Characterization of the film is being conducted using a Manson x-ray source with six different anodes, building on previous research to improve analysis methods.
- Results from the Agfa D4 film characterization at both the Manson source and the Stanford Synchrotron Radiation Lightsource Beamline 16-2 are compared, highlighting improvements and reduced uncertainties in the characterization process.
Corrigendum to "TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43" [Neurobiology of disease Volume 193, April 2024, 106437].
Juan M Godoy-Corchuelo Zeinab Ali Jose M Brito Armas Aurea B Martins-Bach Irene García-Toledo Thomas J Cunningham
Neurobiol Dis
November 2024
Article Synopsis
- Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder that causes extremely high LDL cholesterol levels, leading to heart disease at an early age; lomitapide is a medication designed to lower these cholesterol levels in affected adults and is being tested for safety and efficacy in children.
- The APH-19 study involved 43 pediatric patients aged 5-17 years on existing cholesterol treatments; they received varying doses of lomitapide over a 24-week period to measure its effect on LDL cholesterol levels and other lipid parameters.
- Results indicated a significant decrease in LDL cholesterol by 53.5% after 24 weeks of treatment, suggesting lomitapide may be effective for managing cholesterol